ÂÜÀòÂÒÂ×

Glenn is Chief Development Officer of BioVersys. He is a distinguished expert in infectious diseases, the author of numerous publications, and the inventor of many patents. Since February 2019 Glenn has led the clinical development activities at BioVersys, applying his 25 years of R&D experience and significant knowledge in the modern development of antibiotics. Glenn obtained his Ph.D. in Biochemistry in 1993 from the University of Basel. Following post-doctoral studies in Basel he has held the following positions; Group Leader at Roche, Head of Biology, Site Head at Morphochem AG, and Scientific Coordinator responsible for pre-clinical research at Arpida. In 2009 he joined Polyphor where he led the Antibiotic Research and Early Development, successfully transitioning Murepavadin (POL7080) from pre-clinical activities to Phase 3 studies. Glenn is an expert in developing and implementing modern antibiotic clinical development plans (e.g. devising pathogen-specific development) and is experienced in presenting to and discussing with European and US regulatory authorities, e.g. scientific advice meetings (MHRA, EMA), Type C meetings (FDA) and End of Phase 2 meeting (FDA).